Advertisement
Canada markets close in 3 hours 13 minutes

  • S&P/TSX

    21,670.54
    -69.66 (-0.32%)
     

  • S&P 500

    5,061.45
    -0.37 (-0.01%)
     

  • DOW

    37,881.27
    +146.16 (+0.39%)
     

  • CAD/USD

    0.7235
    -0.0018 (-0.25%)
     

  • CRUDE OIL

    85.35
    -0.06 (-0.07%)
     

  • Bitcoin CAD

    85,828.12
    -2,939.16 (-3.31%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,407.30
    +24.30 (+1.02%)
     

  • RUSSELL 2000

    1,969.33
    -6.38 (-0.32%)
     

  • 10-Yr Bond

    4.6570
    +0.0290 (+0.63%)
     

  • NASDAQ

    15,891.97
    +6.95 (+0.04%)
     

  • VOLATILITY

    18.36
    -0.87 (-4.52%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6809
    -0.0015 (-0.22%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS COMPANY EARNINGS ROLL IN

Shares of Live Nation, parent company of Ticketmaster, fall on antitrust probe report

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - October 20, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20574&wire=5



Allegations against SAVA include that the Company made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

ADVERTISEMENT

If you suffered a loss in Cassava you have until October 26, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100356